Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intranasal ketamine for acute cluster headache attacks-Results from a proof-of-concept open-label trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Timing and durability of response to erenumab in patients with chronic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Paracetamol use during pregnancy - a call for precautionary action

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Poor social support and loneliness in chronic headache: Prevalence and effect modifiers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Health-related quality of life in tension-type headache: a population-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Objective: To investigate the safety and efficacy of intranasal ketamine for the treatment of a single cluster headache (CH) attack. Background: Acute treatment options for patients with CH who have an insufficient response to oxygen and triptans are limited. Intranasal ketamine has anecdotally been successful in treating a CH attack. Methods: We conducted an open-label pilot study enrolling 23 patients with chronic CH (International Classification of Headache Disorders, 3rd edition), and of these, 20 patients treated a single CH attack with intranasal ketamine. Under in-hospital observation, patients received 15 mg of intranasal ketamine every 6 min a maximum of five times. The primary endpoint was a 50% reduction in pain intensity within 15 min after initiating treatment. Results: The primary endpoint was not met; 15 min after the first ketamine administration, the mean reduction in pain intensity was 1.1 (95% confidence interval [CI]: −0.6 to 2.7, p = 0.188) on the numeric rating scale (NRS), equivalent to a 15% reduction in pain intensity. However, 30 min after the first application, the pain intensity was reduced by 59% on an 11-point NRS (mean difference: 4.3, 95% CI: 2.4–6.2, p < 0.001, N = 16) and 11 out of 16 (69%) scored 4 or below on the NRS. Four patients received rescue medication 15 min after the first ketamine application and were therefore excluded from the analysis at 30 min. Half of the patients preferred ketamine to oxygen and/or sumatriptan injection. No serious adverse events were identified during the trial. Conclusion: Intranasal ketamine may be an effective acute treatment for CH at 30 min but should be tested in a larger controlled design. Patients and physicians should be conscious of the abuse potential of ketamine.

OriginalsprogEngelsk
Artikelnummer14220
TidsskriftHeadache
Vol/bind62
Udgave nummer1
Sider (fra-til)26-35
Antal sider10
ISSN0017-8748
DOI
StatusUdgivet - jan. 2022

Bibliografisk note

© 2021 American Headache Society.

ID: 69275031